<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Costa VD</submitter><funding>CSIC Grupos-908 I+D</funding><funding>ANII</funding><funding>CAP</funding><funding>CSIC Iniciación</funding><funding>Comisión Sectorial de Investigación Científica</funding><funding>Agencia Nacional de Investigación e Innovación</funding><funding>PEDECIBA</funding><pagination>12047</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9570357</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>23(19)</volume><pubmed_abstract>Lung cancer is the first leading cause of cancer-related deaths in the world. Aberrant glycosylation in lung tumors leads to the expression of tumor-associated carbohydrate structures, such as the Tn antigen, consisting of &lt;i>N&lt;/i>-acetyl-galactosamine (GalNAc) linked to a serine or threonine residue in proteins (α-GalNAc-O-Ser/Thr). The Tn antigen can be recognized by the Macrophage Galactose/GalNAc lectin (MGL), which mediates various immune regulatory and tolerogenic functions, mainly by reprogramming the maturation of function of dendritic cells (DCs). In this work, we generated two different Tn-expressing variants from the Lewis-type lung murine cancer cell line LL/2, which showed different alterations in the &lt;i>O&lt;/i>-glycosylation pathways that influenced the interaction with mouse M</pubmed_abstract><journal>International journal of molecular sciences</journal><pubmed_title>Lung Tumor Cells with Different Tn Antigen Expression Present Distinctive Immunomodulatory Properties.</pubmed_title><pmcid>PMC9570357</pmcid><funding_grant_id>FCE1-2017-1-136094</funding_grant_id><funding_grant_id>Grupos-908 I+D</funding_grant_id><funding_grant_id>to Teresa Freire and Valeria da Costa</funding_grant_id><funding_grant_id>CSIC-Iniciación</funding_grant_id><funding_grant_id>ID114</funding_grant_id><pubmed_authors>Rodriguez-Zraquia SA</pubmed_authors><pubmed_authors>Marino KV</pubmed_authors><pubmed_authors>Lores P</pubmed_authors><pubmed_authors>Costa VD</pubmed_authors><pubmed_authors>Costa M</pubmed_authors><pubmed_authors>Rabinovich GA</pubmed_authors><pubmed_authors>Freire T</pubmed_authors><pubmed_authors>Landeira M</pubmed_authors><pubmed_authors>Festari MF</pubmed_authors><pubmed_authors>van Vliet SJ</pubmed_authors></additional><is_claimable>false</is_claimable><name>Lung Tumor Cells with Different Tn Antigen Expression Present Distinctive Immunomodulatory Properties.</name><description>Lung cancer is the first leading cause of cancer-related deaths in the world. Aberrant glycosylation in lung tumors leads to the expression of tumor-associated carbohydrate structures, such as the Tn antigen, consisting of &lt;i>N&lt;/i>-acetyl-galactosamine (GalNAc) linked to a serine or threonine residue in proteins (α-GalNAc-O-Ser/Thr). The Tn antigen can be recognized by the Macrophage Galactose/GalNAc lectin (MGL), which mediates various immune regulatory and tolerogenic functions, mainly by reprogramming the maturation of function of dendritic cells (DCs). In this work, we generated two different Tn-expressing variants from the Lewis-type lung murine cancer cell line LL/2, which showed different alterations in the &lt;i>O&lt;/i>-glycosylation pathways that influenced the interaction with mouse M</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Oct</publication><modification>2025-04-04T09:29:57.596Z</modification><creation>2024-11-06T04:34:13.733Z</creation></dates><accession>S-EPMC9570357</accession><cross_references><pubmed>36233358</pubmed><doi>10.3390/ijms231912047</doi></cross_references></HashMap>